Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Publication year range
1.
Neurology ; 54(3): 666-73, 2000 Feb 08.
Article in English | MEDLINE | ID: mdl-10680801

ABSTRACT

OBJECTIVE: To study the possible specific response to recombinant tissue plasminogen activator (rtPA) thrombolysis of anterior choroidal artery (AChA) stroke. BACKGROUND: Outcome and response after rtPA thrombolysis are possibly better in small-vessel infarcts, but a specific study of AChA stroke has not yet been performed. METHODS: The authors proposed an open trial of IV rtPA within 7 hours in patients age 20 and 81 years with all types of internal carotid artery territory stroke if the baseline Scandinavian Stroke Scale (SSS) score was less than 48. A dose of rtPA 0.8 mg/kg was infused over 90 minutes. Of 114 consecutive patients, 9 patients (7.9%) exhibited hypodensity in the AChA territory on day 1 brain CT. RESULTS: Seven of nine patients with AChA infarct had a primary early recovery within 6 hours after the initiation of rtPA infusion. In addition, recovery was complete in five patients and partial in two patients. No intracerebral hematoma was observed. Three patients had a "reinfarct syndrome" at 12, 25, and 48 hours respectively. However, in the two latter patients treated with IV heparin, the deficit disappeared again with the increase of heparin dose in one patient and disappeared spontaneously in the other patient. The overall outcome at day 90 was six total recoveries in nine patients (66%). Patients with a final good outcome had a slight "unstructured" hypodensity in the AChA territory on day 1 brain CT, whereas patients with a bad outcome had the classic "structured" hypodensity of AChA territory stroke. CONCLUSION: These data support a specific quick response of AChA territory stroke to IV rtPA thrombolysis, probably due to the small size of the artery and of the "clot." The high frequency of the reinfarct syndrome is a clinical fact that is difficult to explain. Efficient heparin treatment after 24 hours may control the reinfarct syndrome in some patients.


Subject(s)
Choroid Plexus/blood supply , Stroke/drug therapy , Tissue Plasminogen Activator/therapeutic use , Aged , Brain/diagnostic imaging , Humans , Injections, Intravenous , Male , Middle Aged , Thrombolytic Therapy , Tomography, X-Ray Computed
2.
Rev Neurol (Paris) ; 155(11): 961-5, 1999 Nov.
Article in French | MEDLINE | ID: mdl-10603641

ABSTRACT

We report the case of a 74 year-old woman who had been treated since 8 years for a Waldenström's disease. She also was affected by a progressive multi-focal leukoencephalopathy. The interest of this case lies in two principal features. On the one hand, the clinical and radiological signs were restricted to the cerebellum and to the brainstem, on the other hand, brain examination revealed lymphocytes and plasma cells infiltration suggestive of an associated Bing and Neel syndrome.


Subject(s)
Cerebellar Diseases/pathology , Cerebellar Diseases/virology , JC Virus/isolation & purification , Leukoencephalopathy, Progressive Multifocal/complications , Lymphocytes, Tumor-Infiltrating/pathology , Papillomavirus Infections/complications , Papillomavirus Infections/virology , Plasma Cells/pathology , Tumor Virus Infections/complications , Tumor Virus Infections/virology , Aged , Antibodies , Antibodies, Viral/immunology , Antigens, Viral/immunology , Cerebellar Diseases/immunology , Diagnosis, Differential , Fatal Outcome , Female , Humans , In Situ Hybridization , Leukoencephalopathy, Progressive Multifocal/pathology , Magnetic Resonance Imaging , Papillomavirus Infections/immunology , Syndrome , Tumor Virus Infections/immunology , Waldenstrom Macroglobulinemia/complications
3.
Stroke ; 29(12): 2529-40, 1998 Dec.
Article in English | MEDLINE | ID: mdl-9836764

ABSTRACT

BACKGROUND AND PURPOSE: Although new, large, double-blind, randomized studies are needed to establish the efficiency of intravenous thrombolysis, open trials of sufficient size may also provide novel data concerning specific outcomes after thrombolysis. METHODS: An open study of intravenous rtPA in 100 patients with internal carotid artery (ICA) territory strokes between 20 and 81 years of age, with a baseline Scandinavian Stroke Scale (SSS) score of <48 at entry was conducted. Inclusion time was within 7 hours after stroke onset. rtPA (0.8 mg/kg) was infused for 90 minutes, with an initial 10% bolus. Heparin was given according to 3 consecutive protocols. The SSS evaluation was done on days 0, 1, 7, 30, and 90. CT scan was performed before treatment, on days 1 and 7. Etiological investigations included echocardiography and carotid Doppler sonography and/or angiography. Outcome at 1 year was documented by SSS score, the modified Rankin Scale (mRS) score, and a 10-point invalidity scale. Multivariate logistic regression was used to identify predictors of poor versus good outcome. RESULTS: At day 90, 45 patients (45%) had a good result, defined as complete regression or slight neurological sequelae (mRS score of 0-1), 18 patients had a moderate outcome (mRS 2-3), and 31 patients had serious neurological sequelae (mRS 4-5). Six patients died, 2 with intracerebral hematoma after immediate heparin. Five of 11 patients (45.5%) treated between 6 and 7 hours had a good result. The overall intracerebral hematoma rate was 7%. Higher values of fibrin degradation products at 2 hours were observed in the subgroup with intracerebral hematomas. Significant predictors of poor outcome on multivariate logistic regression analysis were baseline SSS score of <15 (odds ratio [OR], 3.38; 95% confidence interval [CI], 1.07 to 10. 74; P=0.04), indistinction between white and gray matter on CT scan (OR, 6.59; 95% CI, 2.19 to 19.79; P=0.0008), and proximal internal carotid thrombosis (OR, 3.29; 95% CI, 0.99 to 10.95; P=0.05). CONCLUSIONS: Our study confirms the safety of intravenous rtPA at a dose of 0.8 mg/kg and suggests efficacy for this drug even within 7 hours. Outcome and hematoma rates were at least as favorable as for trials of therapy with a 3-hour time window. Subgroups with a poor prognosis include low baseline neurological score, baseline CT changes, and proximal ICA thrombosis. However, approximately 30% of patients with each of these characteristics show a good outcome, so their inclusion in future routine rtPA protocols is still justified.


Subject(s)
Carotid Artery Diseases/drug therapy , Cerebrovascular Disorders/drug therapy , Fibrinolytic Agents/therapeutic use , Thrombolytic Therapy , Tissue Plasminogen Activator/therapeutic use , Adult , Aged , Carotid Artery Diseases/diagnostic imaging , Carotid Artery Diseases/etiology , Cerebrovascular Disorders/diagnosis , Cerebrovascular Disorders/etiology , Female , Humans , Injections, Intravenous , Male , Middle Aged , Recombinant Proteins , Tomography, X-Ray Computed , Treatment Outcome
4.
Stroke ; 27(5): 882-90, 1996 May.
Article in English | MEDLINE | ID: mdl-8623108

ABSTRACT

BACKGROUND AND PURPOSE: Pilot studies using early thrombolytic therapy in stroke have suggested that recombinant tissue plasminogen activator (rTPA) might be effective. While large, double-blind, randomized studies are needed, open trials could generate hypotheses concerning (1) the clinical correlations of outcome, (2) the significance of CT scan data during the first week, and (3) the use of adjunctive therapies. METHODS: We performed an open trial of intravenous rTPA on patients referred to our emergency service with all types of ischemic stroke in the carotid territory. All patients between 20 and 81 years hospitalized during 1994 with completed stroke in the internal carotid artery territory and a baseline Scandinavian Stroke Scale score lower than 48, even with severe disturbances of consciousness, were included. The inclusion time was within 7 hours after stroke onset. A 0.8-mg/kg dose of rTPA was infused for 90 minutes. Intravenous heparin was given either immediately at efficient dosage or after 24 hours. Mannitol was used in patients with severe presentation. The Scandinavian Stroke Scale evaluation was done at baseline, 3 hours, and 1, 7, 30, and 90 days. The CT scan was performed before the treatment and at days 1 (24 +/- 6 hours) and 7. RESULTS: Forty-three consecutive patients met the criteria of the protocol. The mean age at inclusion was 65 +/- 10.4 years, and the mean interval to treatment was 232 +/- 79 minutes. At day 90, 25 patients (58.1%) exhibited a complete regression of symptoms, and 3 had moderate neurological sequelae. Thirteen patients had severe neurological sequelae, 11 with infarcts and 2 with secondary parenchymal hematomas. Two patients died (4.6%), 1 with hematoma. The overall hematoma rate was 6.9%. Excellent outcome at day 90 was significantly correlated with major neurological improvement at day 1. Intravenous immediate heparin versus delayed heparin after 24 hours improved the ischemic outcome but not the overall outcome. Reinfarction syndromes after major neurological improvement, likely to be rethrombosis syndromes, were observed in 3 patients (6.9%). For the day 1 CT scan, poor outcome was associated with the presence of structured and homogeneous hypodensities likely to represent classic infarcts, as confirmed by day 7 CT scan. Conversely, total recovery was significantly associated with the absence of any image or with unstructured hypodensities, a particular type of image characterized by its heterogeneous darkness and often polylobar shape. This type of image disappeared at day 7 in 17.6% of the cases and is likely to represent reperfusion images and/or incomplete ischemic damage. CONCLUSIONS: The results obtained in this open, small study suggest safety and effectiveness of rTPA thrombolysis at the dose of 0.8 mg/kg within 7 hours in acute strokes of the carotid territory, including highly serious baseline neurological presentations, until age 81 years and under special therapeutic conditions. Complete recovery is significantly associated with major neurological improvement during the first 24 hours and the presence of a particular type of image at day 1 CT scan characterized by an unstructured hypodensity, often polylobar and heterogeneous, which is likely to correspond to reperfusion images.


Subject(s)
Arterial Occlusive Diseases/drug therapy , Brain Ischemia/drug therapy , Tissue Plasminogen Activator/therapeutic use , Adult , Aged , Aged, 80 and over , Arterial Occlusive Diseases/diagnostic imaging , Arterial Occlusive Diseases/mortality , Brain Ischemia/diagnostic imaging , Brain Ischemia/mortality , Carotid Arteries , Carotid Artery Thrombosis/diagnostic imaging , Carotid Artery Thrombosis/drug therapy , Carotid Artery Thrombosis/mortality , Carotid Artery, Internal , Female , Humans , Infusions, Intravenous , Male , Middle Aged , Recombinant Proteins/administration & dosage , Recombinant Proteins/therapeutic use , Survival Rate , Tissue Plasminogen Activator/administration & dosage , Tomography, X-Ray Computed , Treatment Outcome
5.
Rev Neurol (Paris) ; 151(12): 708-13, 1995 Dec.
Article in French | MEDLINE | ID: mdl-8787101

ABSTRACT

We propose a serotonergic hypothesis for cerebellar ataxia. The levorotatory form of 5 hydroxytryptophan has been shown to be partially active in subtypes of cerebellar ataxia, including cerebellar cortical atrophy (CCA). Buspirone, a 5-HT1A agonist usable in human medicine, has been studied in a group of 14 patients with cerebellar cortical atrophy. Patients were given Buspirone for 2 months. The evaluation of cerebellar ataxia was made by a semi-quantitative scale, 10 fully quantitative measures and measurements of the sway path and sway area of the center of gravity at posturography. The primary endpoints were the modifications of the ataxia scores. At 2 months, the decrease of the ataxia scores was significant, both in the intention-to-treat (14 cases) and target (11 cases) populations. In the target population, secondary endpoints like the time measurements for pronouncing a standard sentence, the time for drawing a ladder and posturographic parameters were significantly improved; the mean global ataxia score was improved by 37.4%. These preliminary data might confirm a link between cerebellar ataxia and the metabolism of serotonin.


Subject(s)
Buspirone/therapeutic use , Cerebellar Ataxia/drug therapy , Serotonin Receptor Agonists/therapeutic use , Adult , Cerebellar Ataxia/physiopathology , Drug Evaluation , Humans , Time Factors
7.
Acta Neurol Scand ; 87(6): 503-4, 1993 Jun.
Article in English | MEDLINE | ID: mdl-8356883

ABSTRACT

We report the occurrence of idiopathic intracranial hypertension in a patient treated with ofloxacin, a fluoroquinolone antimicrobial agent, for 16 months. The withdrawal of ofloxacin and acetazolamide therapy were followed by a complete recovery of visual function.


Subject(s)
Femoral Fractures/complications , Ofloxacin/adverse effects , Osteitis/drug therapy , Pseudotumor Cerebri/chemically induced , Acetazolamide/therapeutic use , Adult , Humans , Intracranial Pressure/drug effects , Long-Term Care , Male , Ofloxacin/therapeutic use , Pseudotumor Cerebri/drug therapy
8.
J Neurol Sci ; 114(2): 160-4, 1993 Feb.
Article in English | MEDLINE | ID: mdl-8445398

ABSTRACT

We studied horizontal saccades by direct-current electro-oculography in 18 patients with internuclear ophthalmoplegia (INO), and in 16 healthy, age-matched subjects. The occurrence of abducting signs, i.e. overshoot and dissociated nystagmus, was related to an increase of interocular dissociation (measured by the ratio of abduction and adduction peak velocities). The amplitude of abduction hypermetria was strongly correlated with the intensity of adduction slowing. These findings support the idea of an adaptive mechanism underlying the overshoot and nystagmus of abduction saccades in INO.


Subject(s)
Ophthalmoplegia/physiopathology , Saccades , Adult , Aged , Electrooculography , Female , Humans , Male , Middle Aged , Photic Stimulation , Reference Values
SELECTION OF CITATIONS
SEARCH DETAIL
...